{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:35:45Z","timestamp":1793111745797,"version":"4.5.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"\u00d6rebro University","id":[{"id":"https:\/\/ror.org\/05kytsw45","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00125-026-06858-4","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:07:57Z","timestamp":1790161677000},"page":"3449-3470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insulin pens and the digital ecosystem"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-1682","authenticated-orcid":false,"given":"Johan","family":"Jendle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7615-9737","authenticated-orcid":false,"given":"Peter","family":"Adolfsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-1657","authenticated-orcid":false,"given":"Roque","family":"Cardona-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2326-4108","authenticated-orcid":false,"given":"Laurent","family":"Crenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-7330","authenticated-orcid":false,"given":"Sergio","family":"Di Molfetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-5596","authenticated-orcid":false,"given":"Dominic","family":"Ehrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-2678","authenticated-orcid":false,"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-6888","authenticated-orcid":false,"given":"Martin","family":"Haluzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-8417","authenticated-orcid":false,"given":"Irl B.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5182-5473","authenticated-orcid":false,"given":"Concetta","family":"Irace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8487-0778","authenticated-orcid":false,"given":"Amy","family":"Jolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-6862","authenticated-orcid":false,"given":"David C.","family":"Klonoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1759-8252","authenticated-orcid":false,"given":"Jens","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-4233","authenticated-orcid":false,"given":"Julia K.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1620-8271","authenticated-orcid":false,"given":"Kirsten","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0951-6949","authenticated-orcid":false,"given":"Jannie Toft Damsgaard","family":"N\u00f8rlev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-3633","authenticated-orcid":false,"given":"Nick","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0588-4880","authenticated-orcid":false,"given":"Ulrik","family":"Pedersen-Bjergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-7263","authenticated-orcid":false,"given":"Eric","family":"Renard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-2881","authenticated-orcid":false,"given":"Sandra","family":"Schlueter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6968-6675","authenticated-orcid":false,"given":"Signe","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2692-8643","authenticated-orcid":false,"given":"Susanne","family":"Reger-Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0009-9598","authenticated-orcid":false,"given":"Inge","family":"van Boxelaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-6207","authenticated-orcid":false,"given":"Emma G.","family":"Wilmot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2493-1304","authenticated-orcid":false,"given":"Lutz","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"6858_CR1","doi-asserted-by":"publisher","first-page":"827484","DOI":"10.3389\/fendo.2022.827484","volume":"13","author":"M Masierek","year":"2022","unstructured":"Masierek M, Nabrdalik K, Janota O, Kwiendacz H, Macherski M, Gumprecht J (2022) The review of insulin pens-past, present, and look to the future. Front Endocrinol (Lausanne) 13:827484. https:\/\/doi.org\/10.3389\/fendo.2022.827484","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"6858_CR2","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s13300-020-00831-z","volume":"11","author":"J Kesavadev","year":"2020","unstructured":"Kesavadev J, Saboo B, Krishna MB, Krishnan G (2020) Evolution of insulin delivery devices: from syringes, pens, and pumps to DIY artificial pancreas. Diabetes Ther 11(6):1251\u20131269. https:\/\/doi.org\/10.1007\/s13300-020-00831-z","journal-title":"Diabetes Ther"},{"issue":"2","key":"6858_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1210\/endrev\/bnac022","volume":"44","author":"M Phillip","year":"2023","unstructured":"Phillip M, Nimri R, Bergenstal RM et al (2023) Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev 44(2):254\u2013280. https:\/\/doi.org\/10.1210\/endrev\/bnac022","journal-title":"Endocr Rev"},{"issue":"1","key":"6858_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-022-05744-z","volume":"66","author":"JL Sherr","year":"2023","unstructured":"Sherr JL, Heinemann L, Fleming GA et al (2023) Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia 66(1):3\u201322. https:\/\/doi.org\/10.1007\/s00125-022-05744-z","journal-title":"Diabetologia"},{"issue":"4","key":"6858_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.mayocp.2025.01.004","volume":"100","author":"DC Klonoff","year":"2025","unstructured":"Klonoff DC, Berard L, Franco DR et al (2025) Advance insulin injection technique and education with FITTER forward expert recommendations. Mayo Clin Proc 100(4):682\u2013699. https:\/\/doi.org\/10.1016\/j.mayocp.2025.01.004","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"6858_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/193229681000400302","volume":"4","author":"JL Selam","year":"2010","unstructured":"Selam JL (2010) Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol 4(3):505\u2013513. https:\/\/doi.org\/10.1177\/193229681000400302","journal-title":"J Diabetes Sci Technol"},{"issue":"11","key":"6858_CR7","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.2337\/dci21-0043","volume":"44","author":"RIG Holt","year":"2021","unstructured":"Holt RIG, DeVries JH, Hess-Fischl A et al (2021) The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 44(11):2589\u20132625. https:\/\/doi.org\/10.2337\/dci21-0043","journal-title":"Diabetes Care"},{"issue":"7","key":"6858_CR8","doi-asserted-by":"publisher","first-page":"e3430","DOI":"10.1002\/dmrr.3430","volume":"37","author":"E Renard","year":"2021","unstructured":"Renard E, Ikegami H, Daher Vianna AG et al (2021) The SAGE study: global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM. Diabetes Metab Res Rev 37(7):e3430. https:\/\/doi.org\/10.1002\/dmrr.3430","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"6858_CR9","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1177\/19322968251366338","volume":"19","author":"SF Petry","year":"2025","unstructured":"Petry SF, Kr\u00fcger M, Uns\u00f6ld C, Heinemann L, Kieble M, Schulz M (2025) 100 million pens a year in Germany: and then in the trash? J Diabetes Sci Technol 19(6):1697\u20131695. https:\/\/doi.org\/10.1177\/19322968251366338","journal-title":"J Diabetes Sci Technol"},{"key":"6858_CR10","unstructured":"NHS England (2024) National diabetes audit type 1 dashboard. https:\/\/digital.nhs.uk\/data-and-information\/clinical-audits-and-registries\/national-diabetes-audit\/dashboards. Accessed 21 Nov 2025"},{"issue":"3","key":"6858_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.sapharm.2023.11.009","volume":"20","author":"K Boonpattharatthiti","year":"2024","unstructured":"Boonpattharatthiti K, Saensook T, Neelapaijit N, Sakunrag I, Krass I, Dhippayom T (2024) The prevalence of adherence to insulin therapy in patients with diabetes: a systematic review and meta-analysis. Res Social Adm Pharm 20(3):255\u2013295. https:\/\/doi.org\/10.1016\/j.sapharm.2023.11.009","journal-title":"Res Social Adm Pharm"},{"issue":"5","key":"6858_CR12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/s2213-8587(20)30042-5","volume":"8","author":"D Ehrmann","year":"2020","unstructured":"Ehrmann D, Kulzer B, Roos T, Haak T, Al-Khatib M, Hermanns N (2020) Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes. Lancet Diabetes Endocrinol 8(5):436\u2013446. https:\/\/doi.org\/10.1016\/s2213-8587(20)30042-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"6858_CR13","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.clinthera.2016.05.009","volume":"38","author":"CV Spain","year":"2016","unstructured":"Spain CV, Wright JJ, Hahn RM, Wivel A, Martin AA (2016) Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther 38(7):1653-1664.e1651. https:\/\/doi.org\/10.1016\/j.clinthera.2016.05.009","journal-title":"Clin Ther"},{"issue":"6","key":"6858_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/dme.12651","volume":"32","author":"I Krass","year":"2015","unstructured":"Krass I, Schieback P, Dhippayom T (2015) Adherence to diabetes medication: a systematic review. Diabet Med 32(6):725\u2013737. https:\/\/doi.org\/10.1111\/dme.12651","journal-title":"Diabet Med"},{"issue":"3","key":"6858_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-018-0421-5","volume":"9","author":"M Perez-Nieves","year":"2018","unstructured":"Perez-Nieves M, Boye KS, Kiljanski J, Cao D, Lage MJ (2018) Adherence to basal insulin therapy among people with type 2 diabetes: a retrospective cohort study of costs and patient outcomes. Diabetes Therapy 9(3):1099\u20131111. https:\/\/doi.org\/10.1007\/s13300-018-0421-5","journal-title":"Diabetes Therapy"},{"issue":"2","key":"6858_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s13300-019-0590-x","volume":"10","author":"B Guerci","year":"2019","unstructured":"Guerci B, Chanan N, Kaur S, Jasso-Mosqueda JG, Lew E (2019) Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Ther 10(2):437\u2013449. https:\/\/doi.org\/10.1007\/s13300-019-0590-x","journal-title":"Diabetes Ther"},{"key":"6858_CR17","doi-asserted-by":"publisher","first-page":"1716587","DOI":"10.3389\/fendo.2025.1716587","volume":"16","author":"JH Jendle","year":"2025","unstructured":"Jendle JH, Garg SK, Thivolet C et al (2025) Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial. Front Endocrinol (Lausanne) 16:1716587. https:\/\/doi.org\/10.3389\/fendo.2025.1716587","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"6858_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4093\/dmj.2024.0130","volume":"49","author":"W Fan","year":"2025","unstructured":"Fan W, Deng C, Xu R et al (2025) Efficacy and safety of automated insulin delivery systems in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab J 49(2):235\u2013251. https:\/\/doi.org\/10.4093\/dmj.2024.0130","journal-title":"Diabetes Metab J"},{"issue":"6","key":"6858_CR19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1177\/19322968241248404","volume":"18","author":"P Adolfsson","year":"2024","unstructured":"Adolfsson P, Hanas R, Zaharieva DP, Dovc K, Jendle J (2024) Automated insulin delivery systems in pediatric type 1 diabetes: a narrative review. J Diabetes Sci Technol 18(6):1324\u20131333. https:\/\/doi.org\/10.1177\/19322968241248404","journal-title":"J Diabetes Sci Technol"},{"issue":"Supplement_1","key":"6858_CR20","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.2337\/dc26-S007","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 7. Diabetes technology: standards of care in diabetes-2026. Diabetes Care 49(Suppl_1):S150-S165. https:\/\/doi.org\/10.2337\/dc26-S007","journal-title":"Diabetes Care"},{"issue":"6","key":"6858_CR21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1159\/000543034","volume":"97","author":"T Biester","year":"2024","unstructured":"Biester T, Berget C, Boughton C et al (2024) International Society for Pediatric and Adolescent Diabetes clinical practice consensus guidelines 2024: diabetes technologies: insulin delivery. Horm Res Paediatr 97(6):636\u2013662. https:\/\/doi.org\/10.1159\/000543034","journal-title":"Hormone Research in Paediatrics"},{"issue":"2","key":"6858_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/pedi.12971","volume":"21","author":"LH Messer","year":"2020","unstructured":"Messer LH, Berget C, Vigers T et al (2020) Real world hybrid closed-loop discontinuation: predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediatr Diabetes 21(2):319\u2013327. https:\/\/doi.org\/10.1111\/pedi.12971","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"6858_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/1932296820985103","volume":"16","author":"CO Usoh","year":"2022","unstructured":"Usoh CO, Johnson CP, Speiser JL, Bundy R, Dharod A, Aloi JA (2022) Real-world efficacy of the hybrid closed-loop system. J Diabetes Sci Technol 16(3):659\u2013662. https:\/\/doi.org\/10.1177\/1932296820985103","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"6858_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/dom.70302","volume":"28","author":"JP Riveline","year":"2026","unstructured":"Riveline JP, Julla JB, Bonnemaison E et al (2026) A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events. Diabetes Obes Metab 28(2):1179\u20131190. https:\/\/doi.org\/10.1111\/dom.70302","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"6858_CR25","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1007\/s00125-024-06165-w","volume":"67","author":"CK Boughton","year":"2024","unstructured":"Boughton CK, Hovorka R (2024) The role of automated insulin delivery technology in diabetes. Diabetologia 67(10):2034\u20132044. https:\/\/doi.org\/10.1007\/s00125-024-06165-w","journal-title":"Diabetologia"},{"issue":"4","key":"6858_CR26","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1177\/19322968251335971","volume":"19","author":"LH Messer","year":"2025","unstructured":"Messer LH, Forlenza GP, Gonder-Frederick L et al (2025) Practical considerations and implementation of automated insulin delivery systems. J Diabetes Sci Technol 19(4):950\u2013957. https:\/\/doi.org\/10.1177\/19322968251335971","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"6858_CR27","doi-asserted-by":"publisher","first-page":"e15196","DOI":"10.1111\/dme.15196","volume":"41","author":"BE Amer","year":"2024","unstructured":"Amer BE, Yaqout YE, Abozaid AM, Afifi E, Aboelkhier MM (2024) Does fully closed-loop automated insulin delivery improve glycaemic control in patients with type 2 diabetes? A meta-analysis of randomized controlled trials. Diabet Med 41(1):e15196. https:\/\/doi.org\/10.1111\/dme.15196","journal-title":"Diabet Med"},{"issue":"Supplement_1","key":"6858_CR28","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.2337\/dc25-S007","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 7. Diabetes technology: standards of care in diabetes\u20142025. Diabetes Care 48(Supplement_1):S146\u2013S166. https:\/\/doi.org\/10.2337\/dc25-S007","journal-title":"Diabetes Care"},{"issue":"10","key":"6858_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/dia.2019.0411","volume":"22","author":"P Adolfsson","year":"2020","unstructured":"Adolfsson P, Hartvig NV, Kaas A, Moller JB, Hellman J (2020) Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen. Diabetes Technol Ther 22(10):709\u2013708. https:\/\/doi.org\/10.1089\/dia.2019.0411","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"6858_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2337\/dc22-0525","volume":"46","author":"F Gomez-Peralta","year":"2023","unstructured":"Gomez-Peralta F, Abreu C, Fernandez-Rubio E et al (2023) Efficacy of a connected insulin pen cap in people with noncontrolled type 1 diabetes: a multicenter randomized clinical trial. Diabetes Care 46(1):206\u2013208. https:\/\/doi.org\/10.2337\/dc22-0525","journal-title":"Diabetes Care"},{"issue":"5","key":"6858_CR31","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s12325-023-02478-1","volume":"40","author":"I Cranston","year":"2023","unstructured":"Cranston I, Jamdade V, Liao B, Newson RS (2023) Clinical, economic, and patient-reported benefits of connected insulin pen systems: a systematic literature review. Adv Ther 40(5):2015\u20132037. https:\/\/doi.org\/10.1007\/s12325-023-02478-1","journal-title":"Adv Ther"},{"issue":"1","key":"6858_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/dom.15316","volume":"26","author":"J Hellman","year":"2024","unstructured":"Hellman J, Hartvig NV, Kaas A, Moller JB, Sorensen MR, Jendle J (2024) Associations of bolus insulin injection frequency and smart pen engagement with glycaemic control in people living with type 1 diabetes. Diabetes Obes Metab 26(1):301\u2013310. https:\/\/doi.org\/10.1111\/dom.15316","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6858_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2337\/dc23-2176","volume":"47","author":"TPA Danne","year":"2024","unstructured":"Danne TPA, Joubert M, Hartvig NV, Kaas A, Knudsen NN, Mader JK (2024) Association between treatment adherence and continuous glucose monitoring outcomes in people with diabetes using smart insulin pens in a real-world setting. Diabetes Care 47(6):995\u20131003. https:\/\/doi.org\/10.2337\/dc23-2176","journal-title":"Diabetes Care"},{"issue":"2","key":"6858_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40271-022-00610-x","volume":"16","author":"J Seo","year":"2023","unstructured":"Seo J, Heidenreich S, Aldalooj E et al (2023) Patients\u2019 preferences for connected insulin pens: a discrete choice experiment among patients with type 1 and type 2 diabetes. Patient 16(2):127\u2013138. https:\/\/doi.org\/10.1007\/s40271-022-00610-x","journal-title":"Patient"},{"issue":"4","key":"6858_CR35","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/19322968221148508","volume":"17","author":"L Heinemann","year":"2023","unstructured":"Heinemann L, Jendle J (2023) Language matters: connected pens, smart pens, connected smart pens, or just digital pens? J Diabetes Sci Technol 17(4):875\u2013877. https:\/\/doi.org\/10.1177\/19322968221148508","journal-title":"J Diabetes Sci Technol"},{"key":"6858_CR36","unstructured":"European Union (2026) European Union's Medical Device Regulation Compliance (EU MDR). https:\/\/www.mastercontrol.com\/compliance\/eu-mdr\/. Accessed 18 Jul 2026"},{"issue":"4","key":"6858_CR37","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1177\/19322968251316577","volume":"20","author":"F Giorgino","year":"2026","unstructured":"Giorgino F, Bonfanti R, Castaldo F et al (2026) The utility of smart multiple daily injection systems in intensive insulin-treated people with diabetes: an Italian expert consensus. J Diabetes Sci Technol 20(4):1450\u20131459. https:\/\/doi.org\/10.1177\/19322968251316577","journal-title":"J Diabetes Sci Technol"},{"issue":"12","key":"6858_CR38","doi-asserted-by":"publisher","first-page":"e70161","DOI":"10.1111\/dme.70161","volume":"42","author":"A Laurenzi","year":"2025","unstructured":"Laurenzi A, Edd SN, Adolfsson P et al (2025) Insights into the effective use of the Smart MDI system: data from the first 1852 type 1 diabetes users. Diabet Med 42(12):e70161. https:\/\/doi.org\/10.1111\/dme.70161","journal-title":"Diabet Med"},{"issue":"4","key":"6858_CR39","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/19322968261448215","volume":"20","author":"JK Mader","year":"2026","unstructured":"Mader JK, Heinemann L, Brandt D et al (2026) Smart pens: expectations regarding use and functionality from health care providers. J Diabetes Sci Technol 20(4):1100\u20131105. https:\/\/doi.org\/10.1177\/19322968261448215","journal-title":"J Diabetes Sci Technol"},{"issue":"11","key":"6858_CR40","doi-asserted-by":"publisher","first-page":"e48998","DOI":"10.7759\/cureus.48998","volume":"15","author":"SMH Ibrahim","year":"2023","unstructured":"Ibrahim SMH, Shahat EA, Amer LA, Aljohani AK (2023) The impact of using carbohydrate counting on managing diabetic patients: a review. Cureus 15(11):e48998. https:\/\/doi.org\/10.7759\/cureus.48998","journal-title":"Cureus"},{"issue":"1","key":"6858_CR41","doi-asserted-by":"publisher","first-page":"e001971","DOI":"10.1136\/bmjdrc-2020-001971","volume":"9","author":"S Sterner Isaksson","year":"2021","unstructured":"Sterner Isaksson S, Bensow Bacos M, Eliasson B et al (2021) Effects of nutrition education using a food-based approach, carbohydrate counting or routine care in type 1 diabetes: 12 months prospective randomized trial. BMJ Open Diabetes Res Care 9(1):e001971. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001971","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"12","key":"6858_CR42","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/children12121668","volume":"12","author":"S Giza","year":"2025","unstructured":"Giza S, Kotanidou EP, Tsinopoulou VR, Poukoulidou T, Ntouma S, Galli-Tsinopoulou A (2025) Can glucose alarm fatigue threaten the absolute clinical benefit of continuous glucose monitoring in optimal glucose management in children and adolescents with type 1 diabetes? A narrative review. Children (Basel) 12(12):1668. https:\/\/doi.org\/10.3390\/children12121668","journal-title":"Children (Basel)"},{"key":"6858_CR43","unstructured":"Prisma Executive (2024) Welcome to the PRISMA website. Available from https:\/\/www.prisma-statement.org. Accessed 12 Jan 2026"},{"issue":"5","key":"6858_CR44","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1177\/19322968211016513","volume":"16","author":"RM Bergenstal","year":"2022","unstructured":"Bergenstal RM, Johnson ML, Aroda VR et al (2022) Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. J Diabetes Sci Technol 16(5):1167\u20131173. https:\/\/doi.org\/10.1177\/19322968211016513","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"6858_CR45","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/dia.2018.0298","volume":"21","author":"RM Bergenstal","year":"2019","unstructured":"Bergenstal RM, Peyrot M, Dreon DM et al (2019) Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther 21(5):273\u2013285. https:\/\/doi.org\/10.1089\/dia.2018.0298","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"6858_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0168-8227(95)01092-R","volume":"28","author":"C Coscelli","year":"1995","unstructured":"Coscelli C, Lostia S, Lunetta M, Nosari I, Coronel GA (1995) Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract 28(3):173\u2013177. https:\/\/doi.org\/10.1016\/0168-8227(95)01092-R","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"6858_CR47","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1185\/03007995.2011.630721","volume":"27","author":"S Garg","year":"2011","unstructured":"Garg S, Bailey T, DeLuzio T, Pollom D (2011) Preference for a new prefilled insulin pen compared with the original pen. Curr Med Res Opin 27(12):2323\u20132333. https:\/\/doi.org\/10.1185\/03007995.2011.630721","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"6858_CR48","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1089\/dia.2019.0427","volume":"22","author":"F Gomez-Peralta","year":"2020","unstructured":"Gomez-Peralta F, Abreu C, Gomez-Rodriguez S et al (2020) Efficacy of insulclock in patients with poorly controlled type 1 diabetes mellitus: a pilot, randomized clinical trial. Diabetes Technol Ther 22(9):686\u2013690. https:\/\/doi.org\/10.1089\/dia.2019.0427","journal-title":"Diabetes Technol Ther"},{"key":"6858_CR49","doi-asserted-by":"publisher","first-page":"1544668","DOI":"10.3389\/fdgth.2025.1544668","volume":"7","author":"L Roth","year":"2025","unstructured":"Roth L, Steckhan N, Schwarz PEH (2025) Impact of a digital application on HbA1c levels in people with diabetes: a randomized controlled trial. Front Digit Health 7:1544668. https:\/\/doi.org\/10.3389\/fdgth.2025.1544668","journal-title":"Front Digit Health"},{"issue":"2","key":"6858_CR50","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1464-5491.1988.tb00962.x","volume":"5","author":"N Saurbrey","year":"1988","unstructured":"Saurbrey N, Arnold-Larsen S, M\u00f8ller-Jensen B, K\u00fchl C (1988) Comparison of continuous subcutaneous insulin infusion with multiple insulin injections using the NovoPen. Diabet Med 5(2):150\u2013153. https:\/\/doi.org\/10.1111\/j.1464-5491.1988.tb00962.x","journal-title":"Diabet Med"},{"issue":"1","key":"6858_CR51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/152091504322783413","volume":"6","author":"NK Valk","year":"2004","unstructured":"Valk NK, Cerny G, Sieber J, Lytzen L, Berg B (2004) Efficacy and safety performance of the Innovo insulin doser. Diabetes Technol Ther 6(1):53\u201358. https:\/\/doi.org\/10.1089\/152091504322783413","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"6858_CR52","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1080\/03007995.2019.1605769","volume":"35","author":"ML Warren","year":"2019","unstructured":"Warren ML, Brod M, H\u00e5kan-Bloch J, Sparre T, Chaykin LB (2019) Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes. Curr Med Res Opin 35(9):1623\u20131629. https:\/\/doi.org\/10.1080\/03007995.2019.1605769","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"6858_CR53","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/pedi.12087","volume":"15","author":"AA Abul-Ainine","year":"2014","unstructured":"Abul-Ainine AA, Abul-Ainine SA (2014) Toddlers\u2019 diabetes: the lost insulin drop and SemiPens vs DeciPen. Pediatr Diabetes 15(4):319\u2013323. https:\/\/doi.org\/10.1111\/pedi.12087","journal-title":"Pediatr Diabetes"},{"issue":"11","key":"6858_CR54","doi-asserted-by":"publisher","first-page":"6507","DOI":"10.1111\/dom.70051","volume":"27","author":"P Adolfsson","year":"2025","unstructured":"Adolfsson P, Guerci B, Hartvig NV, Kaas A, Nyg\u00e5rd Knudsen N, Mader JK (2025) Glycaemic control after connected insulin pen initiation in people living with diabetes: results from a real-world setting. Diabetes Obes Metab 27(11):6507\u20136515. https:\/\/doi.org\/10.1111\/dom.70051","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"6858_CR55","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1185\/03007995.2012.698258","volume":"28","author":"P Adolfsson","year":"2012","unstructured":"Adolfsson P, Veijola R, Huot C, Hansen HD, Lademann JB, Phillip M (2012) Safety and patient perception of an insulin pen with simple memory function for children and adolescents with type 1 diabetes\u2013the REMIND study. Curr Med Res Opin 28(9):1455\u20131463. https:\/\/doi.org\/10.1185\/03007995.2012.698258","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"6858_CR56","doi-asserted-by":"publisher","first-page":"e14555","DOI":"10.7759\/cureus.14555","volume":"13","author":"A Al Hayek","year":"2021","unstructured":"Al Hayek A, Al Dawish M (2021) Patient-reported preference and clinical efficacy of insulin pen devices with safety needles in adolescents and young adults with type 1 diabetes: a prospective study. Cureus 13(4):e14555. https:\/\/doi.org\/10.7759\/cureus.14555","journal-title":"Cureus"},{"issue":"3","key":"6858_CR57","first-page":"155","volume":"6","author":"JF Bak","year":"1987","unstructured":"Bak JF, Nielsen OH, Pedersen O, Beck-Nielsen H (1987) Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients. Diabetes Res 6(3):155\u2013158","journal-title":"Diabetes Res"},{"issue":"4","key":"6858_CR58","first-page":"315","volume":"124","author":"G Carta","year":"1988","unstructured":"Carta G, Borgoglio A, Borgoglio MG, Granata L, Cordera R, Adezati L (1988) Clinical experience with optimized therapy of insulin dependent diabetes mellitus using NovoPen. Clin Ter 124(4):315\u2013320","journal-title":"Clin Ter"},{"key":"6858_CR59","doi-asserted-by":"publisher","first-page":"112377","DOI":"10.1016\/j.diabres.2025.112377","volume":"226","author":"A Chico","year":"2025","unstructured":"Chico A, Pazos-Couselo M, Nattero-Chavez L et al (2025) Beyond glycemic metrics: real-world benefits of connected insulin pens in type 1 diabetes. Diabetes Res Clin Pract 226:112377. https:\/\/doi.org\/10.1016\/j.diabres.2025.112377","journal-title":"Diabetes Res Clin Pract"},{"key":"6858_CR60","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1089\/dia.2024.78502.abstracts","volume":"27","author":"A Courtney","year":"2025","unstructured":"Courtney A, Comerford S, Owens L (2025) Real-world outcomes of smart insulin pens in adults with diabetes mellitus attending an Irish tertiary hospital. Diabetes Technol Ther 27:e148\u2013e149. https:\/\/doi.org\/10.1089\/dia.2024.78502.abstracts","journal-title":"Diabetes Technol Ther"},{"key":"6858_CR61","doi-asserted-by":"publisher","first-page":"112191","DOI":"10.1016\/j.diabres.2025.112191","volume":"224","author":"JT Damsgaard N\u00f8rlev","year":"2025","unstructured":"Damsgaard N\u00f8rlev JT, Kronborg T, Jensen MH, Rana P, Vestergaard P, Hangaard S (2025) Assessment of basal insulin adherence in people with type 2 diabetes in telemonitoring: post-hoc analysis of novel data modalities including insulin injection data. Diabetes Res Clin Pract 224:112191. https:\/\/doi.org\/10.1016\/j.diabres.2025.112191","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"6858_CR62","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/bf02948414","volume":"160","author":"SF Dinneen","year":"1991","unstructured":"Dinneen SF, Cronin CC, O\u2019Sullivan DJ (1991) Long term efficacy of a pen injector. Ir J Med Sci 160(9):286\u2013287. https:\/\/doi.org\/10.1007\/bf02948414","journal-title":"Ir J Med Sci"},{"issue":"20","key":"6858_CR63","first-page":"1335","volume":"149","author":"J Ditzel","year":"1987","unstructured":"Ditzel J, Clemmensen NK (1987) A comparative study of intensive conventional insulin treatment and a multiple insulin-injection regimen with NovoPen. Ugeskr Laeger 149(20):1335\u20131338","journal-title":"Ugeskr Laeger"},{"key":"6858_CR64","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1089\/dia.2024.78502.abstracts","volume":"27","author":"K Dov\u010d","year":"2025","unstructured":"Dov\u010d K, Poulsen AT, Kaas A, Schmitt C, Mj S, Battelino T (2025) Detecting and describing hypoglycaemic episodes using connected insulin pens and continuous glucose monitoring (CGM) DATA. Diabetes Technol Ther 27:e76\u2013e77. https:\/\/doi.org\/10.1089\/dia.2024.78502.abstracts","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"6858_CR65","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/19322968221104142","volume":"18","author":"NR Ekberg","year":"2024","unstructured":"Ekberg NR, Hartvig NV, Kaas A, Moller JB, Adolfsson P (2024) Smart pen exposes missed basal insulin injections and reveals the impact on glycemic control in adults with type 1 diabetes. J Diabetes Sci Technol 18(1):66\u201373. https:\/\/doi.org\/10.1177\/19322968221104142","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"6858_CR66","first-page":"97","volume":"11","author":"MA Gall","year":"1989","unstructured":"Gall MA, Mathiesen ER, Sk\u00f8tt P et al (1989) Effect of multiple insulin injections with a pen injector on metabolic control and general well-being in insulin-dependent diabetes mellitus. Diabetes Res 11(2):97\u2013101","journal-title":"Diabetes Res"},{"key":"6858_CR67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3233\/shti240335","volume":"316","author":"IE Giese","year":"2024","unstructured":"Giese IE, Jensen MH, Kronborg T, S\u00f8ndergaard TH, Hangaard S (2024) Identifying patterns in long term CGM and insulin data - an explorative study. Stud Health Technol Inform 316:21\u201322. https:\/\/doi.org\/10.3233\/shti240335","journal-title":"Stud Health Technol Inform"},{"issue":"4","key":"6858_CR68","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/dia.2018.0361","volume":"21","author":"F Gomez-Peralta","year":"2019","unstructured":"Gomez-Peralta F, Abreu C, Gomez-Rodriguez S, Ruiz L (2019) Insulclock: a novel insulin delivery optimization and tracking system. Diabetes Technol Ther 21(4):209\u2013214. https:\/\/doi.org\/10.1089\/dia.2018.0361","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"6858_CR69","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/dia.2024.0356","volume":"27","author":"F Gomez-Peralta","year":"2025","unstructured":"Gomez-Peralta F, Abreu C, Santos E et al (2025) A telehealth program using continuous glucose monitoring and a connected insulin pen cap in nursing homes for older adults with insulin-treated diabetes: the trescasas study. Diabetes Technol Ther 27(5):357\u2013365. https:\/\/doi.org\/10.1089\/dia.2024.0356","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"6858_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/dia.2023.0321","volume":"26","author":"F Gomez-Peralta","year":"2024","unstructured":"Gomez-Peralta F, Valledor X, Lopez-Picado A et al (2024) Ultrarapid insulin use can reduce postprandial hyperglycemia and late hypoglycemia, even in delayed insulin injections: a connected insulin cap-based real-world study. Diabetes Technol Ther 26(1):1\u201310. https:\/\/doi.org\/10.1089\/dia.2023.0321","journal-title":"Diabetes Technol Ther"},{"key":"6858_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.mmm.2025.09.009","author":"P Gourdy","year":"2025","unstructured":"Gourdy P, Benhamou PY, Joubert M et al (2025) Improvement in time in range (TIR) after introduction of a connected insulin pen in routine clinical practice in France. Med Mal Metab 20(5):496\u2013503. https:\/\/doi.org\/10.1016\/j.mmm.2025.09.009","journal-title":"Med Mal Metab"},{"issue":"1","key":"6858_CR72","doi-asserted-by":"publisher","first-page":"e5482","DOI":"10.1097\/md.0000000000005482","volume":"96","author":"L Guo","year":"2017","unstructured":"Guo L, Xiao X, Sun X, Qi C (2017) Comparison of jet injector and insulin pen in controlling plasma glucose and insulin concentrations in type 2 diabetic patients. Medicine (Baltimore) 96(1):e5482. https:\/\/doi.org\/10.1097\/md.0000000000005482","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"6858_CR73","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5455\/medarh.2017.71.391-395","volume":"71","author":"S Hasanbegovic","year":"2017","unstructured":"Hasanbegovic S, Obarcanin E, Hasanbegovic E, Begic N (2017) Impact of insulin delivery method on hypoglycemia incidence in pediatric type 1 diabetes mellitus patients. Med Arch 71(6):391\u2013395. https:\/\/doi.org\/10.5455\/medarh.2017.71.391-395","journal-title":"Med Arch"},{"issue":"5","key":"6858_CR74","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1464-5491.1989.tb01196.x","volume":"6","author":"CM Houtzagers","year":"1989","unstructured":"Houtzagers CM, Berntzen PA, van der Stap H et al (1989) Efficacy and acceptance of two intensified conventional insulin therapy regimens: a long-term cross-over comparison. Diabet Med 6(5):416\u2013421. https:\/\/doi.org\/10.1111\/j.1464-5491.1989.tb01196.x","journal-title":"Diabet Med"},{"key":"6858_CR75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/mder.s59229","volume":"9","author":"J Hyllested-Winge","year":"2016","unstructured":"Hyllested-Winge J, Sparre T, Pedersen LK (2016) NovoPen Echo(\u00ae) insulin delivery device. Med Devices (Auckl) 9:11\u201318. https:\/\/doi.org\/10.2147\/mder.s59229","journal-title":"Med Devices (Auckl)"},{"issue":"44","key":"6858_CR76","first-page":"3567","volume":"155","author":"MK Jensen","year":"1993","unstructured":"Jensen MK, Ditzel J, Lervang HH, Jensen S, Pedersen JO (1993) Short-term and long-term effects on glycosylated hemoglobin after transition from conventional insulin treatment to multiple insulin injection regime in a diabetic outpatient clinic. Ugeskr Laeger 155(44):3567\u20133571","journal-title":"Ugeskr Laeger"},{"issue":"3","key":"6858_CR77","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4093\/dmj.2025.0112","volume":"50","author":"SY Kwon","year":"2026","unstructured":"Kwon SY, Kwak H, Kim JH (2026) Effectiveness of the stage 4 smart insulin pen DIA:CONN P8 for glycemic control in a real-world setting. Diabetes Metab J 50(3):612\u2013617. https:\/\/doi.org\/10.4093\/dmj.2025.0112","journal-title":"Diabetes Metab J"},{"issue":"1","key":"6858_CR78","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1089\/dia.2023.0365","volume":"26","author":"J MacLeod","year":"2024","unstructured":"MacLeod J, Im GH, Smith M, Vigersky RA (2024) Shining the spotlight on multiple daily insulin therapy: real-world evidence of the InPen smart insulin pen. Diabetes Technol Ther 26(1):33\u201339. https:\/\/doi.org\/10.1089\/dia.2023.0365","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"6858_CR79","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2337\/dc18-1631","volume":"42","author":"MN Munshi","year":"2019","unstructured":"Munshi MN, Slyne C, Greenberg JM et al (2019) Nonadherence to insulin therapy detected by bluetooth-enabled pen cap is associated with poor glycemic control. Diabetes Care 42(6):1129\u20131131. https:\/\/doi.org\/10.2337\/dc18-1631","journal-title":"Diabetes Care"},{"issue":"1","key":"6858_CR80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/diabetology6010007","volume":"6","author":"P Pantanetti","year":"2025","unstructured":"Pantanetti P, Cangelosi G, Morales Palomares S et al (2025) Real-world life analysis of a continuous glucose monitoring and smart insulin pen system in type 1 diabetes: a cohort study. Diabetology 6(1):7. https:\/\/doi.org\/10.3390\/diabetology6010007","journal-title":"Diabetology"},{"key":"6858_CR81","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1089\/dia.2024.78502.abstracts","volume":"27","author":"P P\u00e9rez-Reyes","year":"2025","unstructured":"P\u00e9rez-Reyes P, Leon-Idougourram S, Rebollo Rom\u00e1n \u00c1, Calle-Castro ML (2025) Impact of smart insulin pens on glycemic control. Diabetes Technol Ther 27:e154\u2013e155. https:\/\/doi.org\/10.1089\/dia.2024.78502.abstracts","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"6858_CR82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/healthcare13010038","volume":"13","author":"V Resi","year":"2024","unstructured":"Resi V, Gaglio A, Pigotskaya Y, Caretto A, Orsi E, Grancini V (2024) Smart insulin pen in pregnant women with type 1 diabetes: an encouraging case series. Healthcare (Basel) 13(1):38. https:\/\/doi.org\/10.3390\/healthcare13010038","journal-title":"Healthcare (Basel)"},{"issue":"6","key":"6858_CR83","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1177\/193229681000400623","volume":"4","author":"C Reynholds","year":"2010","unstructured":"Reynholds C, Antal Z (2010) Analysis of the NovoPen\u00ae Echo for the delivery of insulin: a comparison of usability, functionality, and preference among pediatric subjects, their parents, and health care professionals. J Diabetes Sci Technol 4(6):1476\u20131478. https:\/\/doi.org\/10.1177\/193229681000400623","journal-title":"J Diabetes Sci Technol"},{"issue":"13","key":"6858_CR84","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1517\/14656566.9.13.2223","volume":"9","author":"B Sommavilla","year":"2008","unstructured":"Sommavilla B, J\u00f8rgensen C, Jensen K (2008) Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother 9(13):2223\u20132232. https:\/\/doi.org\/10.1517\/14656566.9.13.2223","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"6858_CR85","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/19322968211058707","volume":"16","author":"T Sparre","year":"2022","unstructured":"Sparre T, Hansen N-AB, Wernersson AS, Guarraia M (2022) Development of an insulin pen is a patient-centric multidisciplinary undertaking: a commentary. J Diabetes Sci Technol 16(3):617\u2013622. https:\/\/doi.org\/10.1177\/19322968211058707","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"6858_CR86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/dia.2019.0186","volume":"22","author":"E Toschi","year":"2020","unstructured":"Toschi E, Slyne C, Greenberg JM et al (2020) Examining the relationship between pre- and postprandial glucose levels and insulin bolus timing using bluetooth-enabled insulin pen cap technology and continuous glucose monitoring. Diabetes Technol Ther 22(1):19\u201324. https:\/\/doi.org\/10.1089\/dia.2019.0186","journal-title":"Diabetes Technol Ther"},{"key":"6858_CR87","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/ppa.s491944","volume":"19","author":"LF Valladales-Restrepo","year":"2025","unstructured":"Valladales-Restrepo LF, Delgado-Araujo AC, Oyuela-Guti\u00e9rrez MC, Ospina-Arzuaga HD, Machado-Alba JE (2025) Level of satisfaction among patients using insulin administered by pen vs vial\/syringe. An observational prospective study. Patient Prefer Adherence 19:65\u201374. https:\/\/doi.org\/10.2147\/ppa.s491944","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"6858_CR88","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s13300-024-01570-1","volume":"15","author":"C-Y Wang","year":"2024","unstructured":"Wang C-Y, Zhou FL, Gandhi AB et al (2024) Real-world effectiveness of the Gla-300 + Cap + App program in adult users living with type 2 diabetes in Taiwan. Diabetes Ther 15(6):1389\u20131401. https:\/\/doi.org\/10.1007\/s13300-024-01570-1","journal-title":"Diabetes Ther"},{"issue":"8","key":"6858_CR89","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1745-7599.2002.tb00138.x","volume":"14","author":"T Wilk","year":"2002","unstructured":"Wilk T, Mora PF, Chaney S, Shaw K (2002) Use of an insulin pen by homeless patients with diabetes mellitus. J Am Acad Nurse Pract 14(8):372\u2013379. https:\/\/doi.org\/10.1111\/j.1745-7599.2002.tb00138.x","journal-title":"J Am Acad Nurse Pract"},{"issue":"5","key":"6858_CR90","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1111\/dom.16249","volume":"27","author":"H Wolpert","year":"2025","unstructured":"Wolpert H, Rodbard D, Xue J, Johnson J, Dassau E (2025) Characterizing insulin dosing behaviour and glycaemic excursions: development of metrics using connected insulin pen and continuous glucose monitoring. Diabetes Obes Metab 27(5):2507\u20132514. https:\/\/doi.org\/10.1111\/dom.16249","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"6858_CR91","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3143\/geriatrics.62.93","volume":"62","author":"A Yamasaki","year":"2025","unstructured":"Yamasaki A, Egashira S, Komatsu Y et al (2025) Introduction of a smart insulin pen in an elderly patient with type 1 diabetes mellitus. Nihon Ronen Igakkai Zasshi 62(1):93\u201399. https:\/\/doi.org\/10.3143\/geriatrics.62.93","journal-title":"Nihon Ronen Igakkai Zasshi"},{"issue":"1","key":"6858_CR92","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1186\/s13063-024-08588-7","volume":"25","author":"CHN Thomsen","year":"2024","unstructured":"Thomsen CHN, N\u00f8rlev JTD, Hangaard S et al (2024) The intelligent diabetes telemonitoring using decision support to treat patients on insulin therapy (DiaTRUST) trial: study protocol for a randomized controlled trial. Trials 25(1):744. https:\/\/doi.org\/10.1186\/s13063-024-08588-7","journal-title":"Trials"},{"issue":"3","key":"6858_CR93","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3803\/EnM.2025.2579","volume":"41","author":"JY Kim","year":"2026","unstructured":"Kim JY, Kim NH, Kwak SH et al (2026) Efficacy and safety of stage 5 connected insulin pens in type 1 or type 2 diabetes: randomized controlled trial protocol (SMART-5 study). Endocrinol Metab 41(3):393\u2013404. https:\/\/doi.org\/10.3803\/EnM.2025.2579","journal-title":"Endocrinol Metab"},{"issue":"3","key":"6858_CR94","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1177\/1932296820983863","volume":"16","author":"L Heinemann","year":"2022","unstructured":"Heinemann L, Schnell O, Gehr B, Schloot NC, Gorgens SW, Gorgen C (2022) Digital diabetes management: a literature review of smart insulin pens. J Diabetes Sci Technol 16(3):587\u2013595. https:\/\/doi.org\/10.1177\/1932296820983863","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"6858_CR95","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S2213-8587(25)00288-8","volume":"14","author":"T Linder","year":"2026","unstructured":"Linder T, Dressler-Steinbach I, Wegener S et al (2026) Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, multicentre, multinational, randomised controlled trial. Lancet Diabetes Endocrinol 14(1):50\u201361. https:\/\/doi.org\/10.1016\/S2213-8587(25)00288-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"#cr-split#-6858_CR96.1","unstructured":"European Parliament and Council of the European Union (2017) Regulation"},{"key":"#cr-split#-6858_CR96.2","unstructured":"(EU) 2017\/745 on medical devices (MDR). Available from https:\/\/eur-lex.europa.eu\/eli\/reg\/2017\/745\/2026-01-01. Accessed 18 Jul 2026"},{"issue":"12","key":"6858_CR97","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.34172\/ijhpm.2021.144","volume":"11","author":"S Van Laere","year":"2022","unstructured":"Van Laere S, Muylle KM, Cornu P (2022) Clinical decision support and new regulatory frameworks for medical devices: are we ready for it? - A viewpoint paper. Int J Health Policy Manag 11(12):3159\u20133163. https:\/\/doi.org\/10.34172\/ijhpm.2021.144","journal-title":"Int J Health Policy Manag"},{"issue":"6","key":"6858_CR98","doi-asserted-by":"publisher","first-page":"844","DOI":"10.7326\/m23-0454","volume":"176","author":"M Bretthauer","year":"2023","unstructured":"Bretthauer M, Gerke S, Hassan C, Ahmad OF, Mori Y (2023) The new European medical device regulation: balancing innovation and patient safety. Ann Intern Med 176(6):844\u2013848. https:\/\/doi.org\/10.7326\/m23-0454","journal-title":"Ann Intern Med"},{"key":"6858_CR99","unstructured":"U.S. Food & Drug Administration (2018) Combination Product Definition Combination Product Types; https:\/\/www.fda.gov\/combination-products\/about-combination-products\/combination-product-definition-combination-product-types. Accessed 18 Jul 2026"},{"key":"6858_CR100","unstructured":"U.S. Department of Health and Human Services FaDA (2013) Technical considerations for pen, jet, and related injectors intended for use with drugs and biological products. Available from https:\/\/www.fda.gov\/files\/about%20fda\/published\/Technical-Considerations-for-Pen--Jet--and-Related-Injectors-Intended-for-Use-with-Drugs-and-Biological-Products.pdf. Accessed 12 Jan 2026"},{"key":"6858_CR101","unstructured":"U.S. Department of Health and Human Services FaDA (2015) Guidance for industry and FDA staff: current good manufacturing practice requirements for combination products. Available from https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/current-good-manufacturing-practice-requirements-combination-products. Accessed 12 Jan 2026"},{"key":"6858_CR102","unstructured":"MarkNtel (2024) Europe smart insulin pens market 2025\u20132030. Available from https:\/\/www.marknteladvisors.com\/research-library\/europe-smart-insulin-pens-market.html. Accessed 18 Jul 2026"},{"key":"6858_CR103","unstructured":"Precedence Research (2024) Global smart insulin pens market size and forecast 2025\u20132034. Available from https:\/\/www.precedenceresearch.com\/smart-insulin-pens-market. Accessed 18 Jul 2026"},{"key":"6858_CR104","unstructured":"dt-report (2025) Digitalisation & technology in diabetes: annual survey on connected care. Available from https:\/\/dt-report.de\/en\/. Accessed 18 Jul 2026"},{"key":"6858_CR105","unstructured":"IQVIA (2021) Optimizing insulin use through smart pens. Available from https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/optimizing-insulin-use-through-smart-pens. Accessed 18 Jul 2026"},{"issue":"1","key":"6858_CR106","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/19322968241274796","volume":"20","author":"L Heinemann","year":"2026","unstructured":"Heinemann L, Sieber J, Kulzer B (2026) Connected pens or smart pens: technology needs context. J Diabetes Sci Technol 20(1):184\u2013192. https:\/\/doi.org\/10.1177\/19322968241274796","journal-title":"J Diabetes Sci Technol"},{"key":"6858_CR107","unstructured":"EUDF (2024) Digital integration in insulin therapy: challenges and opportunities. Available from https:\/\/www.eudf.org\/publications\/. Accessed 18 Jul 2026"},{"issue":"6","key":"6858_CR108","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1177\/19322968241268235","volume":"19","author":"DC Klonoff","year":"2025","unstructured":"Klonoff DC, Aaron RE, Tian T, Espinoza JC (2025) Principles of interoperability of diabetes devices. J Diabetes Sci Technol 19(6):1681\u20131686. https:\/\/doi.org\/10.1177\/19322968241268235","journal-title":"J Diabetes Sci Technol"},{"key":"6858_CR109","unstructured":"Diabetes Technology Society (2026) iCoDE-2 Standard Project. Available from https:\/\/www.diabetestechnology.org\/icode\/icode2.shtml. Accessed 18 Jul 2026"},{"issue":"1","key":"6858_CR110","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2337\/cd22-0068","volume":"41","author":"E Ospelt","year":"2022","unstructured":"Ospelt E, Noor N, Sanchez J et al (2022) Facilitators and barriers to smart insulin pen use: a mixed-method study of multidisciplinary stakeholders from diabetes teams in the United States. Clin Diabetes 41(1):56\u201367. https:\/\/doi.org\/10.2337\/cd22-0068","journal-title":"Clin Diabetes"},{"issue":"4","key":"6858_CR111","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2337\/ds18-0069","volume":"32","author":"NA Sangave","year":"2019","unstructured":"Sangave NA, Aungst TD, Patel DK (2019) Smart connected insulin pens, caps, and attachments: a review of the future of diabetes technology. Diabetes Spectr 32(4):378\u2013384. https:\/\/doi.org\/10.2337\/ds18-0069","journal-title":"Diabetes Spectr"},{"key":"6858_CR112","unstructured":"OECD (2024) Biosimilar adoption and insulin procurement in Europe. Available from https:\/\/www.oecd.org\/health\/generics-and-biosimilars_2bcec977.htm. Accessed 18 Jul 2026"},{"key":"6858_CR113","unstructured":"Federal Institute for Drugs and Medical Devices (2024) Digital health applications (DiGA): evaluation framework. Available from https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/EN\/MedicalDevices\/DiGA_Guide.pdf. Accessed 18 Jul 2026"},{"issue":"8","key":"6858_CR114","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s13300-025-01767-y","volume":"16","author":"A Ponce-Ibarra","year":"2025","unstructured":"Ponce-Ibarra A, Hennies N, Newson RS, Artime E, Spaepen E, Kempe HP (2025) Perceptions of suboptimal insulin dosing from people with diabetes and healthcare professionals in Germany. Diabetes Ther 16(8):1727\u20131743. https:\/\/doi.org\/10.1007\/s13300-025-01767-y","journal-title":"Diabetes Ther"},{"issue":"1","key":"6858_CR115","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12875-024-02390-9","volume":"25","author":"RS Newson","year":"2024","unstructured":"Newson RS, Spaepen E, Liao B et al (2024) Understanding suboptimal insulin use in type 1 and 2 diabetes: a cross-sectional survey of healthcare providers who treat people with diabetes. BMC Prim Care 25(1):124. https:\/\/doi.org\/10.1186\/s12875-024-02390-9","journal-title":"BMC Prim Care"},{"issue":"8","key":"6858_CR116","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/dom.12927","volume":"19","author":"D Mauricio","year":"2017","unstructured":"Mauricio D, Meneghini L, Seufert J et al (2017) Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab 19(8):1155\u20131164. https:\/\/doi.org\/10.1111\/dom.12927","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"6858_CR117","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40618-018-0951-8","volume":"42","author":"D Giugliano","year":"2019","unstructured":"Giugliano D, Maiorino MI, Bellastella G, Esposito K (2019) Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. J Endocrinol Invest 42(5):495\u2013503. https:\/\/doi.org\/10.1007\/s40618-018-0951-8","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"6858_CR118","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/07853890.2021.1925148","volume":"53","author":"R Mehta","year":"2021","unstructured":"Mehta R, Goldenberg R, Katselnik D, Kuritzky L (2021) Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Ann Med 53(1):999\u20131010. https:\/\/doi.org\/10.1080\/07853890.2021.1925148","journal-title":"Ann Med"},{"issue":"4","key":"6858_CR119","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/dom.12626","volume":"18","author":"K Khunti","year":"2016","unstructured":"Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK (2016) Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab 18(4):401\u2013409. https:\/\/doi.org\/10.1111\/dom.12626","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"6858_CR120","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/dom.13088","volume":"20","author":"K Khunti","year":"2018","unstructured":"Khunti K, Gomes MB, Pocock S et al (2018) Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab 20(2):427\u2013437. https:\/\/doi.org\/10.1111\/dom.13088","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"6858_CR121","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s13300-022-01245-9","volume":"13","author":"AG Unnikrishnan","year":"2022","unstructured":"Unnikrishnan AG, Viswanathan V, Zhou FL et al (2022) Impact of my dose coach app frequency of use on clinical outcomes in type 2 diabetes. Diabetes Ther 13(5):983\u2013993. https:\/\/doi.org\/10.1007\/s13300-022-01245-9","journal-title":"Diabetes Ther"},{"key":"6858_CR122","unstructured":"Novo Nordisk (2025) Dose check what patients need to know;. Available from https:\/\/www.novonordisk.com\/our-products\/smart-pens\/dose-check.html. Accessed 2 Dec 2025"},{"issue":"2","key":"6858_CR123","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00125-023-06049-5","volume":"67","author":"J Jendle","year":"2024","unstructured":"Jendle J, Adolfsson P, Choudhary P et al (2024) A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU\/UK\/US perspective. Diabetologia 67(2):236\u2013245. https:\/\/doi.org\/10.1007\/s00125-023-06049-5","journal-title":"Diabetologia"},{"issue":"1","key":"6858_CR124","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/19322968231207888","volume":"18","author":"RE Aaron","year":"2024","unstructured":"Aaron RE, Tian T, Yeung AM, Huang J, Klonoff DC, Espinoza JC (2024) The launch of the iCoDE-2 Standard Project: integration of connected diabetes device data into the electronic health record. J Diabetes Sci Technol 18(1):82\u201388. https:\/\/doi.org\/10.1177\/19322968231207888","journal-title":"J Diabetes Sci Technol"},{"key":"6858_CR125","doi-asserted-by":"publisher","unstructured":"Hossmann S, Tan S, Mader JK et al (2025) One size does not fit all: the need for sex-specific precision medicine in diabetes technology. J Diabetes Sci Technol May 25:19322968251340673. https:\/\/doi.org\/10.1177\/19322968251340673","DOI":"10.1177\/19322968251340673"},{"issue":"10","key":"6858_CR126","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s00125-024-06240-2","volume":"67","author":"G Maltese","year":"2024","unstructured":"Maltese G, McAuley SA, Trawley S, Sinclair AJ (2024) Ageing well with diabetes: the role of technology. Diabetologia 67(10):2085\u20132102. https:\/\/doi.org\/10.1007\/s00125-024-06240-2","journal-title":"Diabetologia"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06858-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06858-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06858-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:53:55Z","timestamp":1793109235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06858-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":127,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["6858"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06858-4","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We thank S. de Portu; employee of MiniMed Inc., for assisting with cross-reference checking.","order":1,"name":"Ethics","label":"Acknowledgements","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"JJ declares acting as a consultant for or receiving lecturing fees from Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, MiniMed, Nordic InfuCare, Novo Nordisk, Sanofi, Tandem and Ypsomed, and has received research grants to the institution from Novo Nordisk and MiniMed. PA declares being an advisor to Abbot Diabetes Care, Dexcom, Eli Lilly, Glucomen, MiniMed, Nordic InfuCare, Novo Nordisk, Sanofi and Tandem, and receiving research grants to the institution from MiniMed, Novo Nordisk, Rubin Medical and Tandem. RC-H has received speaker and advisory honoraria from Abbott, Dexcom, Eli Lilly, MiniMed, Novo Nordisk and Sanofi, and serves on behalf of his institution as principal investigator in studies promoted by Diamyd Medical AB, Eli Lilly, Novartis and Sanofi. LC declares being a consultant for or receiving lecturing fees from Abbott Diabetes Care, Dexcom, Eli Lilly, Insulet, MiniMed, Novo Nordisk, Roche Diagnostics Belgium and Sanofi, and receiving research grants to the institution from Roche and Dexcom. SDM has received honoraria from Ascensia Diabetes Care, MOVI SpA, Roche Diabetes Care and Theras Lifetech, and has served on advisory boards for Ascensia Diabetes Care, MOVI SpA, Menarini Diagnostics, Roche Diabetes Care, Sanofi-Aventis and Theras Lifetech. DE has received advisory board member fees from Dexcom Germany and Roche Diabetes Care, as well as honoraria for lectures from Abbott Diabetes Care, Dexcom Germany, Sanofi-Aventis Germany, Boehringer Ingelheim\/Eli Lilly, Eli Lilly and Roche Diabetes Care. FG has received consulting fees from Eli Lilly and Novo Nordisk, grants from Eli Lilly and Roche Diabetes Care, support for attending meetings\/travel from AstraZeneca, Boehringer Ingelheim, Eli Lilly, LifeScan, Merck Sharp & Dohme, MiniMed, Novo Nordisk, Roche Diabetes Care and Sanofi-Aventis, fees for participation on advisory boards from AstraZeneca, Boehringer Ingelheim, Eli Lilly, LifeScan, Merck Sharp & Dohme, Medimmune, MiniMed, Novo Nordisk, Roche Diabetes Care and Sanofi, received support for medical writing and statistical analysis from AstraZeneca, Eli Lilly, Novo Nordisk and Sanofi-Aventis and declares unpaid leadership for EASD\/EFSD, Societ\u00e0 Italiana di Endocrinologia (SIE) and Fo.Ri.SIE. MH received a grant from Sanofi, lecturer fees from Eli Lilly, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Sanofi, Zentiva, Amgen, GSK, Merck and Abbott, and has served on advisory boards for Sanofi, Eli Lilly, Novo Nordisk, Abbott, AstraZeneca, Boehringer Ingelheim, Sanofi, Zentiva, Amgen, GSK and Merck. IBH has received grants from Sequel Med Tech and Cour Pharma, and consultancy fees from Abbott, Roche and Hagar. CI has provided advisory board services for Abbott, Ascensia, MiniMed, Novo Nordisk and Roche Diabetes Care Italy, and received speaker fees from Abbott, Ascensia, Dexcom, Eli Lilly, MOVI and Novo Nordisk. AJ has received speaker honoraria from Dexcom, MiniMed, Roche Diabetes Care and Insulet, and provided advisory board services for mylife Diabetescare, MiniMed and Dexcom. DCK has been a consultant for Afon, Atropos Health, Biowear, Embecta, Glooko, Glucotrack, Lifecare, Sanofi, SynchNeuro and Thirdwayv. JK has received speaking fees from Abbott GmbH and Co. KG, AstraZeneca, Boehringer Ingelheim, Dexcom, MiniMed, Perfood, Lilly, Roche, Sanofi-Aventis and VitalAire. JKM is a member of the advisory boards of Abbott Diabetes Care, Becton-Dickinson, Biomea Fusion, Dexcom, Eli Lilly, Embecta, Insulet, MiniMed, Novo Nordisk A\/S, Pharmasens, Roche Diabetes Care, Sanofi-Aventis and Tandem, has received speaker honoraria from A. Menarini Diagnostics, Abbott Diabetes Care, Buzud, Dexcom, Embecta, Eli Lilly, Novo Nordisk A\/S, Roche Diabetes Care, Sanofi, SinoCare, Viatris and Ypsomed, is a shareholder of decide Clinical Software GmbH and elyte Diagnostics, and serves as CMO of elyte Diagnostics. KN serves on behalf of her institution as an advisor to MiniMed, Tandem, Abbott Diabetes Care, Convatec and Novo Nordisk, owns stocks in Novo Nordisk, has received research grants to the institution from Novo Nordisk, Zealand Pharma, Dexcom, and MiniMed, and has received fees for speaking from MiniMed, Abbott Diabetes Care and Novo Nordisk. JTDN declares that there are no relationships or activities that might bias, or be perceived to bias, their work. NO has received research funding from Dexcom, MiniMed, and Roche Diabetes, and has received speaker or consultancy fees from Dexcom, MiniMed, Roche Diabetes, Tandem, AstraZeneca and Sanofi. UP-B has received speaker fees from Abbott and Novo Nordisk, has been an advisor for Novo Nordisk and Tandem Diabetes Care, has received research support from Novo Nordisk, and also serves on the editorial board of Diabetologia. ER declares consultant\/speaker fees from A. Menarini Diagnostics, Abbott, Air Liquide SI, AstraZeneca, Becton-Dickinson, Boehringer Ingelheim, Cellnovo, Dexcom Inc., Eli Lilly, Hillo, Insulet Inc., Johnson & Johnson (Animas, LifeScan), MiniMed, Medirio, Novo Nordisk, Roche and Sanofi-Aventis, and research support from Abbott, Dexcom Inc., Insulet Inc., Roche, and Tandem Diabetes Care. SSchlueter declares speaker\/advisory board or consulting honoraria from Abbott, Ascensia, Berlin-Chemie, Dexcom, Diabeloop, Glooko, Lilly, Insulet, MiniMed, Menarini, Novo Nordisk, Roche, Sanofi, ViCentra and Ypsomed. SSchmidt declares consulting honoraria from Novo Nordisk A\/S, Abbott and Hedia APS, and speaker honoraria from Novo Nordisk A\/S and Nordic InfuCare, and she was employed by Novo Nordisk A\/S from 2022 to 2023. SR-T declares receiving honoraria for lectures, consulting and advisory and\/or funded research from Abbott, Amgen, Apo Science, Applied Therapeutics, AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Dexcom, Eli Lilly, Hoffmann-La Roche, Insulet, MiniMed, NeoplasMed, Novartis, Novo Nordisk, Sanofi-Aventis and SinoCare. IvB has received speaker honoraria from Abbott, Insulet, MiniMed, Menarini, Novo Nordisk, Sanofi and ViCentra, and has provided advisory board services for Diabeter, Glooko and Roche Diagnostics. EGW has received speaker\/advisory board or consulting honoraria from Abbott, AstraZeneca, Dexcom, Eli Lilly, Embecta, Insulet, MiniMed, Novo Nordisk, Roche, Sanofi, Sinocare, Tandem and Ypsomed, and research support from Abbott, Embecta, Insulet, Novo Nordisk and Sanofi. LH has acted as a consultant for Abbott, Boydsense, Lifecare (Board of Directors), MiniMed EU, Dexcom Germany, Roche, Liom and Perfood, and is a shareholder of Profil Institute Holding GmbH, Neuss, Science Consulting in Diabetes GmbH, D\u00fcsseldorf and diateam GmbH, Bad Mergentheim, Germany.","order":2,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors were responsible for drafting the article and reviewing it critically for important intellectual content. All authors approved the version to be published.","order":3,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}